CKLF instigates a 'cold' microenvironment to promote MYCN-mediated tumor aggressiveness
Name:
CKLF instigates a....pdf
Size:
7.344Mb
Format:
PDF
Description:
Found with Open Access Button
Authors
Qin, X. D.Lam, A.
Zhang, X.
Sengupta, S.
Iorgulescu, J. B.
Ni, H. R.
Das, S.
Rager, M.
Zhou, Z. W.
Zuo, T.
Meara, G. K.
Floru, A. E.
Kemet, C.
Veerapaneni, D.
Kashy, D.
Lin, L.
Lloyd, K.
Kwok, L.
Smith, K. S.
Nagaraju, Raghavendar T
Meijers, R.
Ceol, C.
Liu, C. T.
Alexandrescu, S.
Wu, C. J.
Keskin, D. B.
George, R. E.
Feng, H.
Affiliation
Colorectal and Peritoneal Oncology Centre, The Christie NHS Foundation Trust, Manchester, UKIssue Date
2024
Metadata
Show full item recordAbstract
Solid tumors, especially those with aberrant MYCN activation, often harbor an immunosuppressive microenvironment to fuel malignant growth and trigger treatment resistance. Despite this knowledge, there are no effective strategies to tackle this problem. We found that chemokine-like factor (CKLF) is highly expressed by various solid tumor cells and transcriptionally up-regulated by MYCN. Using the MYCN-driven high-risk neuroblastoma as a model system, we demonstrated that as early as the premalignant stage, tumor cells secrete CKLF to attract CCR4-expressing CD4(+) cells, inducing immunosuppression and tumor aggression. Genetic depletion of CD4(+) T regulatory cells abolishes the immunorestrictive and protumorigenic effects of CKLF. Our work supports that disrupting CKLF-mediated cross-talk between tumor and CD4(+) suppressor cells represents a promising immunotherapeutic approach to battling MYCN-driven tumors.Citation
Qin XD, Lam A, Zhang X, Sengupta S, Iorgulescu JB, Ni HR, et al. CKLF instigates a "cold" microenvironment to promote MYCN-mediated tumor aggressiveness. Science advances. 2024 MAR 15;10(11). PubMed PMID: WOS:001190089500011. English.Journal
Sciences AdvancesDOI
10.1126/sciadv.adh9547PubMed ID
38489372Additional Links
https://dx.doi.org/10.1126/sciadv.adh9547Type
ArticleLanguage
enae974a485f413a2113503eed53cd6c53
10.1126/sciadv.adh9547
Scopus Count
Collections
Related articles
- Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma.
- Authors: Seier JA, Reinhardt J, Saraf K, Ng SS, Layer JP, Corvino D, Althoff K, Giordano FA, Schramm A, Fischer M, Hölzel M
- Issue date: 2021 May
- GD2 redirected CAR T and activated NK-cell-mediated secretion of IFNγ overcomes MYCN-dependent IDO1 inhibition, contributing to neuroblastoma cell immune escape.
- Authors: Caforio M, Sorino C, Caruana I, Weber G, Camera A, Cifaldi L, De Angelis B, Del Bufalo F, Vitale A, Goffredo BM, De Vito R, Fruci D, Quintarelli C, Fanciulli M, Locatelli F, Folgiero V
- Issue date: 2021 Mar
- miR-15a-5p, miR-15b-5p, and miR-16-5p inhibit tumor progression by directly targeting MYCN in neuroblastoma.
- Authors: Chava S, Reynolds CP, Pathania AS, Gorantla S, Poluektova LY, Coulter DW, Gupta SC, Pandey MK, Challagundla KB
- Issue date: 2020 Jan
- GAS7 Deficiency Promotes Metastasis in MYCN-Driven Neuroblastoma.
- Authors: Dong Z, Yeo KS, Lopez G, Zhang C, Dankert Eggum EN, Rokita JL, Ung CY, Levee TM, Her ZP, Howe CJ, Hou X, van Ree JH, Li S, He S, Tao T, Fritchie K, Torres-Mora J, Lehman JS, Meves A, Razidlo GL, Rathi KS, Weroha SJ, Look AT, van Deursen JM, Li H, Westendorf JJ, Maris JM, Zhu S
- Issue date: 2021 Jun 1
- Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
- Authors: Tajiri T, Liu X, Thompson PM, Tanaka S, Suita S, Zhao H, Maris JM, Prendergast GC, Hogarty MD
- Issue date: 2003 Aug 15